Who
Naseem Amin
Director
Company insider
Files Form 4 as: Director, Avadel Pharmaceuticals; Director, Bellerophon Therapeutics.
In numbers
- Trades disclosed
- 31
- Buys
- 3
- Sells
- 0
- Bought
- $400K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 29 Jun 2015
- Last trade
- 12 Feb 2026
- Last filed
- 12 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Feb 2026filed 12 Feb 2026 | Avadel PharmaceuticalsBiotechnology | SEC FORM 4 Code D | $462K22,000 at $21.00 | filing |
| 12 Feb 2026filed 12 Feb 2026 | Avadel Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —49,500 | filing |
| 12 Feb 2026filed 12 Feb 2026 | Avadel Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —11,000 | filing |
| 12 Feb 2026filed 12 Feb 2026 | Avadel Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —49,500 | filing |
| 12 Feb 2026filed 12 Feb 2026 | Avadel Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —11,000 | filing |
| 12 Feb 2026filed 12 Feb 2026 | Avadel Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —11,000 | filing |
| 12 Feb 2026filed 12 Feb 2026 | Avadel Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —11,000 | filing |
| 12 Feb 2026filed 12 Feb 2026 | Avadel Pharmaceuticals | SEC FORM 4 Code D | $462K22,000 at $21.00 | filing |
| 29 Jul 2025filed 31 Jul 2025 | Avadel Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —11,000 at $0.00 | filing |
| 29 Jul 2025filed 31 Jul 2025 | Avadel Pharmaceuticals | SEC FORM 4 Code A | —11,000 at $0.00 | filing |
| 30 Jul 2024filed 1 Aug 2024 | Avadel Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —11,000 at $0.00 | filing |
| 30 Jul 2024filed 1 Aug 2024 | Avadel Pharmaceuticals | SEC FORM 4 Code A | —11,000 at $0.00 | filing |
| 17 May 2024filed 21 May 2024 | Avadel Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —49,500 at $0.00 | filing |
| 7 Jun 2023filed 9 Jun 2023 | Bellerophon Therapeutics | SEC FORM 4 Code A | —47,578 at $0.00 | filing |
| 10 Feb 2023filed 14 Feb 2023 | Bellerophon Therapeutics | SEC FORM 4 Code A | —84,000 at $0.00 | filing |
| 31 Dec 2021filed 4 Jan 2022 | Bellerophon Therapeuticsoption or derivative | SEC FORM 4 Code A | $27K8,671 at $3.10 | filing |
| 31 Dec 2021filed 4 Jan 2022 | Bellerophon Therapeutics | SEC FORM 4 Code A | —39,032 at $0.00 | filing |
| 10 Sep 2020filed 14 Sep 2020 | Bellerophon Therapeuticsoption or derivative | SEC FORM 4 Code A | $66K6,509 at $10.12 | filing |
| 26 Sep 2019filed 30 Sep 2019 | Bellerophon Therapeuticsoption or derivative | SEC FORM 4 Code A | —46,266 at $0.00 | filing |
| 25 Jan 2019filed 25 Jan 2019 | Bellerophon Therapeutics | SEC FORM 4 Bought | $400K571,429 at $0.70 | filing |
News
No headline names them, or the companies they trade most, lately.